Skip to content

Growth of Infants Fed an Extensively Hydrolyzed Infant Formula

Assessment of Growth of Infants Fed a 100% Whey Extensively Hydrolyzed Formula.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01210391
Enrollment
282
Registered
2010-09-28
Start date
2010-11-30
Completion date
2013-07-31
Last updated
2014-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth

Brief summary

The primary objective of the clinical trial is to compare growth in infants (expressed as weight gain in g/day) consuming a new extensively hydrolyzed formula (EHF) to infants consuming a commercially available EHF.

Interventions

OTHERExtensively hydrolyzed whey infant formula

New hydrolyzed infant formula.

Commercially available infant formula.

Sponsors

Société des Produits Nestlé (SPN)
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
11 Days to 4 Months
Healthy volunteers
Yes

Inclusion criteria

* Healthy newborn singleton infant * Full-term (\>= 37 weeks gestation) * Birth weight between \>= 2500 and \< =4500 g * 14 ± 3 days of age on enrollment * Infant's mother has elected not to breastfeed * baby has been exclusively formula fed a minimum of 3 days prior to enrollment * Study explained and written information provided with Parent/Caregiver * Informed consent signed (parent/legal representative)

Exclusion criteria

* Congenital illness or malformation affecting infant feeding and/or growth * Suspected or known allergy to cow's milk protein * Significant pre-natal and/or post-natal disease * Any readmission to hospital (except for hyperbilirubinemia) prior to enrollment * Infant has received oral or IV antibiotic therapy in the 10 days prior to enrollment * Infant receiving prescription medication (with exception of topical antibiotics and/or treatment for thrush) or frequent use of over the counter medications except vitamin and mineral supplements * Infant has received probiotics in the seven days prior to enrollment * Infant currently participating in another clinical study * Infant's family who in the Investigator's assessment cannot be expected to comply with the protocol

Design outcomes

Primary

MeasureTime frameDescription
Weight Gain4 MonthsMean weight gain (g/day) from enrollment to 4 months of age.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026